Camrelizumab
- Generic Name
- Camrelizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1798286-48-2
- Unique Ingredient Identifier
- 73096E137E
- Background
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
- Indication
⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。
⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。
⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。
⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2020-06-11
- Target Recruit Count
- 59
- Registration Number
- NCT04425135
Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 396
- Registration Number
- NCT04426955
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）
- Conditions
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- Yanqiao Zhang
- Registration Number
- NCT04420130
The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT04415385
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 21
- Registration Number
- NCT04393506
- Locations
- 🇨🇳
Shanghai Ninth People's Hospital, Shanghai, Shanghai, China
Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2022-02-03
- Target Recruit Count
- 62
- Registration Number
- NCT04390945
- Locations
- 🇨🇳
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 89
- Registration Number
- NCT04379739
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shang'ai, Shanghai, China
Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT04367025
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, China
Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2023-02-22
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 100
- Registration Number
- NCT04365049
- Locations
- 🇨🇳
Frist Affliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04351308
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.